18β-glycyrrhetinic acid regulates mitochondrial ribosomal protein L35-associated apoptosis signaling pathways to inhibit proliferation of gastric carcinoma cells

Abstract

BACKGROUND Gastric carcinoma (GC) is a common gastrointestinal malignancy worldwide. Based on the cancer-related mortality, the current prevention and treatment strategies for GC still show poor clinical results. Therefore, it is important to find effective drug treatment targets. AIM To explore the mechanism by which 18β-glycyrrhetinic acid (18β-GRA) regulates mitochondrial ribosomal protein L35 (MRPL35) related signal proteins to inhibit the proliferation of GC cells. METHODS Cell counting kit-8 assay was used to detect the effects of 18β-GRA on the survival rate of human normal gastric mucosal cell line GES-1 and the proliferation of GC cell lines MGC80-3 and BGC-823. The apoptosis and cell cycle were assessed by flow cytometry. Cell invasion and migration were evaluated by Transwell assay, and cell scratch test was used to detect cell migration. Furthermore, a tumor model was established by hypodermic injection of 2.5 × 10 6 BGC-823 cells at the selected positions of BALB/c nude mice to determine the effect of 18β-GRA on GC cell proliferation, and quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was used to detect MRPL35 expression in the engrafted tumors in mice. We used the term tandem mass tag (TMT) labeling combined with liquid chromatography–tandem mass spectrometry to screen for differentially expressed proteins (DEPs) extracted from GC cells and control cells after 18β-GRA intervention. A detailed bioinformatics analysis of these DEPs was performed, including Gene Ontology annotation and enrichment analysis, Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis, and so on. Moreover, STRING database ( ) was used to predict protein-protein interaction (PPI) relationships and Western blot was used to detect the expression of proteins of interest in GC cells. RESULTS The results indicated that 18β-GRA could inhibit the proliferation of GC cells in a dose- and time-dependent manner. It could induce GC cell apoptosis and arrest the cell cycle at G0/G1 phase. The proportion of cells arrested at S phase decreased with the increase of 18-GRA dose, and the migration and invasiveness of GC cells were inhibited. The results of animal experiments showed that 18β-GRA could inhibit tumor formation in BALB/c nude mice, and qRT-PCR results showed that MRPL35 expression level was significantly reduced in the engrafted tumors in mice. Using TMT technology, 609 DEPs, among which 335 were up-regulated and 274 were down-regulated, were identified in 18β-GRA intervention compared with control. We found that the intervention of 18β-GRA in GC cells involved many important biological processes and signaling pathways, such as cellular processes, biological regulation, and TP53 signaling pathway. Notably, after the drug intervention, MRPL35 expression was significantly down-regulated ( ...

Mechanism of pachymic acid in the treatment of gastric cancer based on network pharmacology and experimental verification

“…Our team previously reported that 18β-glycyrrhetinic acid, a natural drug component, affects the proliferation and metastasis of GC[ 21 ]. PA also appears to be useful as a natural product for the treatment of GC.…”

Melatonin promotes cell cycle progression of neural stem cells subjected to manganese via Nurr1

“…8 The cell cycle consists of the following stages: the first gap (G 1 ) phase, which is dominated by the synthesis of RNA and ribosomes; the synthesis (S) phase, which is focused on DNA replication; the second gap (G 2 ) phase, which involves preparation for mitosis; and the mitotic (M) phase. 9 The cell cycle is co-regulated by Cyclin and Cyclindependent kinases (CDKs), in which Cyclin is responsible for coordinating various checkpoints that govern progression through the phases. When the Cyclin-CDK complex interacts with CDK inhibitor proteins, including proteins of the INK4 family and CIP/KIP family, the activity will be inhibited.…”

“…Among these processes, the investigation of the cell cycle, for example by following the expression of cell cycle‐related molecules, has provided important clues to the process of neurogenesis, especially during embryonic development 8 . The cell cycle consists of the following stages: the first gap (G 1 ) phase, which is dominated by the synthesis of RNA and ribosomes; the synthesis (S) phase, which is focused on DNA replication; the second gap (G 2 ) phase, which involves preparation for mitosis; and the mitotic (M) phase 9 . The cell cycle is co‐regulated by Cyclin and Cyclin‐dependent kinases (CDKs), in which Cyclin is responsible for coordinating various checkpoints that govern progression through the phases.…”

Exploring the molecular mechanism of glycyrrhetinic acid in the treatment of gastric cancer based on network pharmacology and experimental validation

“…In addition, some studies have reported that 18β-GRA can inhibit the invasion and migration of GC cells through the ROS/PKC-α/ERK pathway [ 19 ]. Recently, it was found that 18β-GRA can regulate the apoptosis signaling pathway associated with MRPL35, and inhibit GC cells proliferation [ 20 ].…”